Wilke A, Doebele C, Zindel A, Lee K, Rieke S, Ceribelli M, Comoglio F, Phelan J, Wang J, Pikman Y, Jahn D, Häupl B, Schneider C, Scheich S, Tosto F, Bohnenberger H, Stauder P, Schnütgen F, Slabicki M, Coulibaly Z, Wolf S, Bojarczuk K, Chapuy B, Brandts C, Stroebel P, Lewis C, Engelke M, Xu X, Kim H, Dang T, Schmitz R, Hodson D, Stegmaier K, Urlaub H, Serve H, Schmitt C, Kreuz F, Knittel G, Rabinowitz J, Reinhardt H, Heiden M, Thomas C, Staudt L, Zenz T, Oellerich T. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2022;139(4):538–553. PMCID: PMC8938936

Ducker G, Ghergurovich J, Mainolfi N, Suri V, Jeong S, Li S, Friedman A, Manfredi M, Gitai Z, Kim H, Rabinowitz J. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017;114(43):11404–11409. PMCID: PMC5664509

Ducker G, Chen L, Morscher R, Ghergurovich J, Esposito M, Teng X, Kang Y, Rabinowitz J. Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Cell Metab. 2016;23(6):1140–1153. PMCID: PMC4909566